Endo Lpa Measurement Family History Ascvd

---
name: endo-lpa-measurement-family-history-ascvd
description: Suggests measuring lipoprotein(a) to inform decision-making about short-term and lifetime ASCVD risk and need to intensify LDL-C-lowering therapy in adult patients with family history of premature ASCVD, personal history of ASCVD, or family history of high lipoprotein(a). Triggers include family history of premature heart disease, personal history of atherosclerotic cardiovascular disease, and family history of high lipoprotein(a).
---

# Lipoprotein(a) measurement for family history of premature ASCVD

## STEP 1 — Gather Information
Collect patient's family history of premature ASCVD, personal history of ASCVD, and family history of high lipoprotein(a).

## STEP 2 — Rule In / Rule Out
If any of the following are present: family history of premature ASCVD, personal history of ASCVD, or family history of high lipoprotein(a), proceed to measure lipoprotein(a); otherwise, do not measure lipoprotein(a) for this indication.

## STEP 3 — Classify or Stratify
Measure lipoprotein(a) and classify as elevated (≥50 mg/dL or ≥125 nmol/L) or not elevated.

## STEP 4 — Decide
If lipoprotein(a) is elevated, consider intensifying LDL-C-lowering therapy; if not elevated, continue current lipid-lowering regimen based on overall risk assessment.

## Clinical Guardrails / Mimics / Pitfalls
Lipoprotein(a) testing does not need to be repeated if previously measured; lipoprotein(a) ≥50 mg/dL is a risk-enhancing factor for ASCVD; reducing lipoprotein(a) has not yet been proven to reduce ASCVD risk; do not use lipoprotein(a) alone to guide therapy without considering overall risk; avoid measuring in patients without the specified indications as it adds little to global risk assessment.

## Concrete Clinical Example
A 45-year-old man reports his father had a myocardial infarction at age 50 (premature ASCVD); he has no personal ASCVD and no prior lipoprotein(a) measurement; lipoprotein(a) is measured at 80 mg/dL; decision made to intensify his statin therapy from moderate to high intensity.

**Source:** Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2020, doi:10.1210/clinem/dgaa674